Andrew D. Jones - 15 Feb 2023 Form 4 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Role
CFO
Signature
/s/ Andrew D. Jones
Issuer symbol
NBY
Transactions as of
15 Feb 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 16:30:55 UTC
Previous filing
06 Dec 2021
Next filing
03 Sep 2024
SEC
View on sec.gov

Andrew D. Jones is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Remarks:

The reporting person departed from his position at NovaBay Pharmaceuticals, Inc., effective February 15, 2023. As a result, the reporting person is no longer subject to Section 16 in connection with his transactions in the equity securities of NovaBay Pharmaceuticals, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.